4 results about "Aberrant cell" patented technology

This invention provides compositions and methods to prevent aberrant cell proliferation in a subject using a single-domain antibody (sdAb) directed against an intracellular component, wherein the aberrant cell proliferation can be cancer. The sdAb is synergistic with one or more chemotherapeutic drugs and improves therapeutic efficacy of the one or more chemotherapeutic drug against cancer. The invention also includes a method of treating viral infections using a sdAb, wherein the sbAb inhibits the replication of viruses such as Ebola virus and Zika virus in infected cells.

The invention relates to the field of binding molecules. In particular, it relates to the field of therapeutic binding molecules for the treatment of diseases involving aberrant cells, such as cancer cells. In particular, it relates to multispecific antibodies that bind an extracellular part of two or more different membrane associated proteins and thereby modulate a biological activity expressed by a cell, and the use of such antibodies in combination therapies.

The disclosure relates to the field of neuregulin-1 (NRG1) fusions, methods for detecting such, identifying or diagnosing patients with such fusions and methods of treatment of a cancer, a tumor or an aberrant cell comprising an NRG1 fusion. Also, it relates to the field of therapeutic (human) compounds for the treatment of subjects with an ErbB-2 / ErbB-3 positive cancer that comprise a NRG1 fusion.